Cancer3.AI: up-to-date cancer knowledge — scientific research, therapies, treatment centers and news
FDA Advisors Recommend Galleri Multicancer Blood Test
An FDA advisory committee narrowly voted in favour of the Galleri multicancer early detection blood test, with margins of 6-4 and 7-2 (one abstention) from the molecular and clinical genetics panel. Panellists expressed clear reservations, reflecting ongoing uncertainty about whether detecting cell-free DNA signals across dozens of tumour types actually reduces cancer mortality rather than merely finding more disease. A favourable FDA decision would make Galleri the first broadly marketed multicancer screening test in the United States, a potential turning point for how population-level cancer screening is organised.
Video of the week
A made-to-measure vaccine against melanoma: how does it work?
Eva, cancer3.ai's AI character, explains in plain language how a personalised mRNA vaccine against melanoma works and what the studies so far have shown.
Eva is an AI character created by cancer3.ai (voice and image generated with ElevenLabs). She is not a doctor and does not replace one. Every factual statement is backed by the sources below.
Sources: Khattak A. i wsp., Journal of Clinical Oncology 2026 — 5-letnia aktualizacja badania fazy 2b KEYNOTE-942 (PubMed 42223134) · Merck / Moderna, 19.08.2026 — komunikat o wynikach badania fazy 3 INTerpath-001 · Nature, 20.08.2026 — co naprawdę pokazało badanie fazy 2b i co dalej
